Review Article

An update on osteoporosis research: effect of calcium plus vitamin D supplementation

Lincon Chandra Shill¹, Nafisa Habib Purba¹, Marjia Sultana¹,
Towhid Hasan¹*, Mahmudur Rahman¹, Nahid Sultana²

¹Department of Food Technology and Nutrition Science, Noakhali Science and Technology University, Noakhali-3814, Bangladesh
²Department of Gynaecology and Obstetrics, Kurmitola General Hospital, Dhaka-1206, Bangladesh

Received: 27 June 2019
Accepted: 13 August 2019

*Correspondence:
Towhid Hasan,
E-mail: towhidhasan07@gmail.com

ABSTRACT

Osteoporosis is the most common systemic skeletal disease characterized by increased bone fragility. There lies an incongruity among research regarding combined supplementation of calcium (Ca) plus vitamin D and loss of bone health. Hence, the present review is aimed to highlight the current development of osteoporosis research and try to solve the inconsistency among the present knowledge. Electronic databases like PubMed, Cochrane Library, and EMBASE were searched from their inception to December 2018 using terms “calcium,” “vitamin D,” and “osteoporosis.” A systemic approach was followed to reach a final of 23 studies assessing the synergetic effect of calcium and vitamin D on osteoporosis and fractures risk. Among the included studies, nineteen have revealed that calcium and vitamin D decrease bone resorption, reduce the incidence of fractures, increase bone mineral density (BMD) and overall bone health. However, no significant osteogenic response was reported in five trials after supplementation with calcium and vitamin D together. Osteoporosis results in a reduced quality of life, increased disability-adjusted life span, and big economic burden to health care systems of countries. Early diagnosis before the occurrence of fractures and by assessing BMD and with early treatment, osteoporosis can be prevented. It is not entirely possible to draw a conclusion regarding beneficial effects of calcium plus vitamin D supplementation; future research based on the fundamentals of bone biology focusing on molecular genetics, and influencing factors of the acquisition of bone mass during growth and bone loss can alleviate present controversies.

Keywords: Osteoporosis, Calcium, Vitamin D

INTRODUCTION

Ageing is a common phenomenon that happens with every human worldwide, and with aging, a gradual loss of bone mass occurs resulting in osteoporosis.¹ Osteoporosis is a chronic metabolic bone disease characterized by low bone density and microarchitectural deterioration of bone tissue with a consequent elevation in bone fragility.² Since bone loss remains asymptomatic and early osteoporosis is not usually diagnosed, osteoporosis is often considered a ‘silent disease’; it does not become clinically evident until fractures occur. Advancement of age is associated with loss of bone density and rates of fracture increase markedly with age, giving rise to significant disability and some deaths.³

Osteoporosis is the most common systemic skeletal disease in humans, representing a major public health problem. Just like hypertension is considered a risk factor for stroke, osteoporosis is for fracture.³ It affects an enormous number of people, of both sexes and all races, and its prevalence will increase as the population ages. It
was estimated that, globally, the number of patients with osteoporotic hip fractures is over 200 million.⁴ According to WHO, osteoporosis is three times more common in women than in men.³ In Europe and the United States, 30% women are reported to be osteoporotic, and a prediction was made that 40% post-menopausal women and 30% men will experience an osteoporotic fracture in near future of their lives.⁵⁻⁷

Osteoporosis can be classified as either primary or secondary by considering the factors affecting bone metabolism. In primary osteoporosis, loss of bone mass occurs in both males and females due to the normal aging process. Bone loss in secondary osteoporosis may result from different types of medications, nutritional deficiencies and chronic medical conditions.⁸

Although the causes of osteoporosis are multifactorial, the most significant are decrease in bone mass, structural deterioration, and enhanced frequency of falls.³ It is widely recommended to use calcium plus vitamin D supplementation for the management of osteoporosis and subsequent fractures; however, recent data shows some inconsistencies in findings. Whereas some studies show that calcium along with vitamin D supplementation minimize the risk of fractures, others argued the statement showing no effect. In recent years, a growing body of scholars have risen a concern that calcium supplementation may be harmful, so some healthcare providers are unwilling to use calcium supplements.⁹ On the other hand, a number of evidences suggest the role of vitamin D to uphold bone health, and healthcare providers are amplifying their research to assess vitamin D status among the population. However, all of these statements are suggestive, many questions are yet to be answered. Hence, the present review was undertaken to provide a better understanding about recent development in osteoporosis research, and whether calcium and vitamin D supplementation together can really benefit individuals with osteoporosis and at risk of becoming osteoporotic.

METHODS

Search strategy

A literature search of the electronic databases of PubMed, Cochrane Library, and EMBASE was carried out from their inception until December 2018. The Medical Subject Headings (MeSH) terms were “calcium,” “vitamin D,” and “osteoporosis.” The reference lists of full articles were also reviewed. Only English language articles were included. The search strategy can be found in Supplemental file 1.

Study selection criteria

We only included the randomized controlled trials conducted on humans that met the following criteria:

Participants

Both healthy individual with no known disorders of bone metabolism or vitamin D deficiency, or primary osteoporotic participants.

Intervention

Both vitamin D (oral or intramuscular vitamin D₂ or vitamin D₃ at any dose and frequency), and calcium (oral calcium salt preparations at any dose and frequency).

Outcome

Non-vertebral fractures, proximal humerus fracture (PHF) and hip fractures, BMD, or incidence of fall.

Studies were excluded if there were enrollment of pregnant women, assessment of the efficacy of only calcium supplementation or only Vit D supplementation on osteoporosis; no treatment, placebo, or lower- or higher-dose vitamin D or calcium regimens as control; short-term (<1 month) treatment; no outcomes of interest for our study.

Data extraction and quality assessment

Two reviewers independently investigated titles, abstracts, and full-text articles, and extracted qualitative and quantitative information from eligible articles, including author and year of study, geographic study location, subjects, treatment modality, duration of follow-up, exposure metric units, number of incidents, and inferences based on analytical comparisons. Any disagreements between them were resolved by consensus. For each included study, one reviewer extracted information about study design, subjects, intervention, and outcomes, and a second reviewer evaluated about completeness and accuracy of the study.

RESULTS

A total of 568 studies were initially searched in this study. Of these, 43 full articles were shortlisted for eligibility assessment. Among the 43 articles, 10 studies were excluded due to irrelevant intervention and 9 studies because the outcomes were not of interest to our study. Finally, 23 eligible articles were included in this study. The results have been shown in Figure 1.

In the present review, 23 randomized controlled trials (RCTs) were included to ascertain the association between supplementation of calcium and vitamin D on osteoporosis. The interventions lasted from 3 months to 7 years enrolling a minimum of 11 subjects to 36,282 subjects. Participants received calcium with a daily dose of 300-3000 mg and vitamin D 400 IU/day to ~14300 IU/day.
Among the included studies, two studies revealed that oral Ca and vitamin D therapy in primary osteoporosis decrease bone resorption. Another eight studies concluded that dietary supplementation with calcium and vitamin D moderately reduces the incidence of non-vertebral fractures, PHF, and hip fractures. Supplementation of both calcium and vitamin D has been found to be beneficial for increasing BMD and improving overall bone health in the eight RCTs. However, no significant osteogenic response was found in the five RCTs after supplementation with both calcium and vitamin D (Table 1).

**DISCUSSION**

It is now well recognized that vitamin D promotes calcium absorption in the gastrointestinal tract and assist in maintaining adequate serum calcium concentrations to enable proper mineralization of the bone. Vitamin D is indispensable for bone growth and bone remodeling by osteoblasts and osteoclasts. 1,25-dihydroxycholecalciferol, the active form of vitamin D metabolite opens up calcium channels in the gut which can further stimulate the formation of calcium binding protein in the intestinal cell, and thereby increases the absorption of calcium from the gut. In this way, optimal circumstances for bone mineralization are created. Mineralization in itself is a passive process in the present of the sufficient calcium and vitamin D. In the vitamin D deficiency, the 1,25-dihydroxycholecalciferol concentration may drop and less calcium will be available for bone mineralization resulting in the decreased bone loss and finally led to osteoporosis. Thus, synergistic action of calcium and vitamin D is crucial for the bone health, particularly to reduce osteoporosis and associated risk of bone fracture.

Identification of strategies to reduce osteoporosis and related fracture risk is imperative, given that osteoporosis and low bone mass is attributed to disability and impaired quality of life of an estimated 53.6 million Americans aged ≥50 years in 2010. The estimation of the total cost associated with osteoporosis is complex and difficult since it includes the costs of acute hospital care, loss of working days for the affected and the family carers, long-term care and medication. However, it is reported that more than two million fractures associated to osteoporosis occur each year in the United States accounting for more than 19 billion US dollar in annual healthcare costs. It has been shown in many surveys that many people do not consume recommended amounts of calcium and vitamin D. Both nutrients are substantial for optimal skeletal health throughout the lifecycle: calcium is the dominant mineral in bone, and vitamin D is important for the efficient absorption of calcium and for adequate functioning of bone cells.
### Table 1: Effects of dietary and supplementary calcium (Ca) and vitamin D (vit D) on osteoporosis.

| Authors, year (ref) | Study location | Subject | Treatment | Duration | Findings |
|---------------------|----------------|---------|-----------|----------|----------|
| Jowsey et al14      | USA            | 11 patients (1 M, 10 F) with progressive osteoporosis | Variable doses of sodium fluoride (30-90 mg/day) and Ca (300-1500 mg/day)+50,000 IU of Vit D twice weekly | 12 to 17 months | Significant increase in bone formation (%) 10.5 vs 3.0; p<0.0005, and decrease in bone resorption (%) 10.7 vs 12.6; p<0.05 |
| Riggs et al15       | USA            | 18 patients (1 M, 17 F) with primary osteoporosis | Group A: 2.0-2.5 g/day Ca+400 IU/day of Vit D Group B: 1.5-2.0 g/day Ca+50,000 units of Vit D twice weekly | Group A: 3-4 months Group B: 3-4 months and 12 months | Group A: Significant decrease (p<0.01) in bone-resorbing surfaces Group B: Significant decrease (p<0.01) in bone forming and bone-resorbing surfaces for both short and long term |
| Inkovaara et al16   | Finland        | 327 (57 M, 270 F) mean age 79.5 y | Combinations of Ca carbonate 3 g, Vit D 1000 IU, methandienone 2.5 mg and/or placebos daily | 9 months | Methandienone reduced osteoporotic activity and increased the muscular mass most effectively Ca carbonate had the poorest effect |
| Chapuy et al17      | France         | 3270 F mean age 84 y | Ca 1200 mg/day+Vit D 800 IU/day vs placebo | 18 months | Significant decrease in the incidence of non-vertebral fractures: 66 vs 97 (p=0.015), and the incidence of hip fractures: 21 vs 37 (p=0.043) than in the placebo group. |
| Eriksson et al18    | Sweden         | 22 F (middle-aged) with post-menopausal osteoporosis | Treatment group: 0.5 mg calcitonin thrice a week subcutaneously + 0.5 μg/day calcitriol orally + 0.5 g/day Ca orally. Control group: 0.5 g/day Ca orally. | 2 y | Insignificant reduction of the BMD of the distal radius and no significant increase in the BMD of the lumbar spine in either group. |
| Hughes et al19      | USA            | 389 (176 M, 213 F) aged ≥65 y | Ca 500 mg/day+Vit D3 700 IU/day vs placebo | 36 months | Lower incidence of non-vertebral fracture among the Ca-Vit D group as compared to the placebo group 5.9% vs 12.9 % (RR: 0.5, 95% CI=0.2-0.9; p=0.02). |
| Baekgaard et al20   | Denmark        | 240 F aged 58-67 y | 1000 mg/day Ca+14 μg/day Vit D3 vs. placebo | 2 y | Increase in lumbar spine BMD among the treatment group at both 1 (p<0.01) and 2y (p<0.05) compared with the placebo. |
| Krieg et al21       | Switzerland    | 248 F aged 62-98 y | 440 IU of Vit D3+500 mg Ca twice daily vs. control | 2 y | Increase in 25-hydroxyvitamin D by 123% (p<0.01), a decrease in PTH by 18% (p<0.05) and an increase in BUA by 1.6% in treatment group. |
| Ringe et al22       | Germany        | 85 patients (55 M, 30 F) on glucocorticoid induced osteoporosis therapy | Group A: 1 μg/day alfacalcidol+500 mg/day Ca Group B: 1000 IU/day Vit D3+500 mg/day Ca | 3 y | Decrease in 25-hydroxy vitamin D by 51% (p<0.01), an increase in PTH by 51% (p<0.01) and a decrease in BUA by 2.3% in the control (p<0.01) No significant change of the lumbar spine density and back pain in the Vit D3 group after treatment. |
| Pfeifer et al23     | Germany        | 148 F (mean age 74 y) with 25-hydroxycholecalciferol level <50 nmol/L | Ca-Vit D group: 1200 mg of Ca+800 IU of Vit D Ca mono group: 1200 mg/day of Ca | 1 y | Incidence of at least one fall: 28% in Ca-mono group vs 16% in Ca-Vit D group (p=0.0373) Mean number of falls: 0.45 in the calcium mono and 0.24 in the Ca-Vit D group (p=0.0346). |
| Authors, year (ref)       | Study location | Subject                                                                 | Treatment                                                                 | Duration | Findings                                                                                                                                 |
|-------------------------|----------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------|
| Son and Chun 24          | Korea          | 69 F with osteopenia aged >65 y                                         | Ca group (1000 mg/day) Alphacalcidol group (0.5 μg/day) and Placebo         | 10 months | Significant increase in Ward’s triangle BMD in the both Ca-supplemented and alphacalcidol group (p<0.05).                                |
| Chapuy et al 25          | France         | 583 F mean age 85.2 y                                                  | Ca-Vit D₃ fixed combination group: Ca 1200 mg/day+Vit D₃ 800 IU/day, Ca-Vit D₃ Separate combination group: Ca 1200 mg/day+Vit D 800 IU/day and placebo | 24 months | The risk ratio for hip fracture in placebo group compared with those in the both treatment group: 1.69 (95% CI=0.96-3).                   |
| Bischoff et al 26        | Switzerland    | 122 F mean age 85.3 y                                                  | Ca+Vit D group:1200 mg/day Ca+800 IU/day cholecalciferol, Ca group: 1200 mg/day Ca | 12 weeks | About 45% reduction of falls in the Ca+Vit D group as compared to Ca group (p<0.01).                                                    |
| Doetsch et al 27         | Denmark        | 30 F mean age 78 y with non-displaced PHF                               | 800 IU/day Vit D₃+1000 mg/day Ca vs. placebo                              | 12 weeks | BMD levels after 12 weeks were significantly higher among the active group compared with the placebo (p<0.02).                             |
| Harwood et al 28         | England        | 150 F with hip fracture                                                | Treatment group 1: single injection of 300,000 units of Vit D₂; Treatment group 2: injected Vit D₂+1 g/day oral Ca; Treatment group 3: 800 units/day oral Vit D₃ + 1 g/day Ca, Placebo | 1 y      | Neck of femur BMD, trochanter BMD and total hip was 2.7%, 3.2% and 3.5% greater respectively than the placebo. Relative risk of fall in the supplemented groups was 0.31 (95% CI=0.08-1.14; p=0.11) compared with placebo. |
| Larsen et al 29          | Denmark        | 9605 (M 3834, F 5771) aged ≥66 y                                       | Ca+Vit D group: 1000 mg/day Ca+400 IU of Vit D, Environmental and health Program group, both intervention group and control group | 3 y      | 16% reduction in fracture incidence rate (RR: 0.84, CI=0.72-0.98; p<0.025) among the Vit D-Ca group.                                   |
| Meier et al 30           | Germany        | 55 (19 M, 36 F) healthy adults aged 33-78 y                            | Oral Vit D₃ 500 IU/day + Ca 500 mg/day vs. placebo                          | 2 y      | Significant increase in bone loss among the controls as compared to treatment group (lumbar spine, p<0.03; femoral neck, p<.05).           |
| Grant et al 31           | England        | 5292 (811 M, 4481 F) aged ≥70 y with low-trauma-fracture              | Group 1: 1000 mg/day Ca, Group 2: 800 IU/day Vit D₂, Group 3: Ca 1000 mg/day+800 IU/day Vit D₃ and Placebo | 62 months | No significant difference of incidence of new, low-trauma fractures between the participants allocated Ca and those who were not HR: 0.94 [95% CI=0.81-1.09]; between group Vit D₂ and those who were not HR: 1.02 [95% CI= 0.88-1.19]; or between group of combination treatment and those assigned placebo HR: 1.01 [95% CI=0.75-1.36] |
| Porthouse et al 32       | England        | 3314 F with one or more risk factors for hip fracture mean age 77 y     | Ca 1000 mg/day+Vit D 800 IU/day+information leaflet on dietary Ca intake and prevention of falls vs. leaflet only (control group) | 25 months | Clinical fracture rates were lower than expected in both groups but did not significantly differ for all clinical fractures (in supplemented group OR for fracture 1.01, 95% CI=0.71-1.43 and OR for hip fracture 0.75, 95% CI=0.31-1.78). |
| Authors, year (ref) | Study location | Subject | Treatment | Duration | Findings |
|---------------------|---------------|---------|-----------|----------|----------|
| Jackson et al\textsuperscript{33} | USA | 36,282 post-menopausal women aged 50-79 y | 1000 mg/day Ca+400 IU/day Vit D\textsubscript{3} vs. Placebo | 7 y | 1.06% higher hip bone density in the Ca+Vit D group than in the placebo group (p<0.01); In the Ca + Vit D group, for hip fracture HR: 0.88 (95% CI=0.72-1.08), for clinical spine fracture HR: 0.90 (0.74-1.10), and for total fractures HR: 0.96 (0.91-1.02) |
| Bolton-Smith et al\textsuperscript{34} | Scotland | 244 F aged ≥60 y | Group 1: Placebo, Group 2: 200 µg/day Vit K\textsubscript{1}, 3. Group 3: 400 IU/day Vit D\textsubscript{3}+1000 mg/day Ca, Group 4: 200 µg/day Vit K\textsubscript{1}+400 IU/day Vit D\textsubscript{3}+1000 mg/day Ca | 2 y | Significant increase in BMD of 0.8%/y (p<0.01) and in BMC (p<0.01) at the ultra-distal radius in the combined Vit K and Vit D plus Ca group |
| Kukuljan et al\textsuperscript{35} | Australia | 180 M aged 50-79 y | Group 1: Exercise+fortified milk (1,000 mg/day Ca and 800 IU/day Vit D\textsubscript{3}), Group 2: Exercise, Group 3: Fortified milk (1,000 mg/day Ca and 800 IU/day Vit D\textsubscript{3}), Group 4: Control | 12 months | About 1.4-1.5% increase in lumbar spine BMD in all treatment groups than controls (all p<0.01) No main effects of fortified milk at any skeletal site |
| Salovaara et al\textsuperscript{36} | Finland | 3432 F aged 65-71 y | 800 IU of D\textsubscript{3} and 1000 mg of Ca as calcium carbonate vs. control | 3 y | Non-significant decreased in the risk of any fracture and any non-vertebral fracture among treatment group by 17% (HR: 0.83, 95% CI=0.81-1.12) and by 13% (HR: 0.87, 95% CI=0.63-1.19), respectively |

Note: BMD: Bone mineral density, BUA: Broad band ultrasound attenuation, CI: Confidence interval, F: Female, HR: Hazard ratio, IU: International unit, M: Male, PTH: Parathyroid hormone, RR: Relative risk, y: Years.
In the present review, an attempt has been made to provide comprehensive detail of the association of calcium and vitamin D supplementation on osteoporosis. From the above studies, it can be revealed that use of calcium and vitamin D supplementation may have a wide-ranging opportunity relating to the management and treatment of osteoporosis. There are a number of evidences which identified that combined supplementation of calcium and vitamin D treatment is significant in the reduction of osteoporosis but some studies are also found to be controversial. However, further comprehensive research is required to investigate the associations between supplementation of calcium and vitamin D and identify the mechanisms behind the reduction of osteoporosis.

CONCLUSION

Osteoporosis and bone loss with an increased risk of fracture is a matter to worry for patients and health care providers. With the increment of age, the long-term upshots of osteoporosis including pain, disability, dependency and institutionalized care will become more prevalent with enormous medical and heavy personnel burden on both the patient’s and nation’s economy. Osteoporosis can be prevented through an early diagnosis before fractures occur and assessment of BMD, and a preliminary treatment regimen will also be beneficial. Also, efforts to avert osteoporosis and bone loss should commence with appropriate education about a healthy lifestyle, including optimal calcium and vitamin D intake, and exercise from adolescence. This education should continue throughout life, with special attention at the time of elevated bone loss such as the menopause transition.

The present study reviews calcium and vitamin D, the cornerstones of bone health. Even though the dietary sources of both nutrients are available, most people do not get adequate amounts for maintaining proper bone health. Additionally, vitamin D synthesis from the skin has been restricted by the profound consciousness of the harmful effects of sunlight. Luckily, supplements are attainable which can supply the body with the necessary amounts for proper bone health.

It is widely recognized that there are genetic, environmental, lifestyle and dietary determinants of risk of osteoporosis, as well as interactions between them. In the present review, combined calcium and vitamin D supplementation has been found to be significantly associated with reduced total bone and hip fractures, improved overall bone health and BMD in most of the studies. But, some RCTs also found no significant positive effect of calcium and vitamin D supplementation on overall bone health. However, due to these inconsistencies of the findings, making any consensus about the effect of supplementation of calcium and vitamin D on osteoporosis is still very crucial. Therefore, to get a better understanding of this area of knowledge, further research should be carried out on fundamental aspects of bone biology, taking into account progress in molecular genetics, and factors influencing the acquisition of bone mass during growth and bone loss during adult life to generate uncontroversial evidence.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: None required

REFERENCES

1. Chen LR, Wen YT, Kuo CL, Chen KH. Calcium and vitamin D supplementation on bone health: current evidence and recommendations. Int J Gerontol. 2014;8(4):183-8.
2. WHO. Prevention and management of osteoporosis. World Health Organization: Geneva, Switzerland; 2003.
3. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization: Geneva, Switzerland; 1994.
4. Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56.
5. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2):4-9.
6. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520-6.
7. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010;16(6):1016-9.
8. Lau EM, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A, et al. The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int. 2001;12(3):239-43.
9. Weaver CM. Calcium supplementation: is protecting against osteoporosis counter to protecting against cardiovascular disease? Curr Osteoporos Rep. 2014;12(2):211-8.
10. Laird E, Ward M, McSorley E, Strain JJ, Wallace J. Vitamin D and bone health: potential mechanisms. Nutrients. 2010;2(7):693-724.
11. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75.
12. Bailey RL, Dodd KW, Goldman JA, Gaheche JJ, Dwyer JT, Moshfegh AJ, et al. Estimation of total
usual calcium and vitamin D intakes in the United States. J Nutr. 2010;140(4):817-22.
13. Wallace TC, Reider C, Fulgoni VL. Calcium and vitamin D disparities are related to gender, age, race, household income level, and weight classification but not vegetarian status in the United States: Analysis of the NHANES 2001-2008 data set. J Am Coll Nutr. 2013;32(5):321-30.
14. Jowsey J, Riggs BL, Kelly PJ, Hoffman DL. Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis. Am J Med. 1972;53(1):43-9.
15. Riggs BL, Jowsey J, Kelly PJ, Hoffman DL, Arnaud CD. Effects of oral therapy with calcium and vitamin D in primary osteoporosis. J Clin Endocrinol Metab. 1976;42(6):1139-44.
16. Inkovaara J, Gothoni G, Halttula R, Heikinheimo R, Tokola O. Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. Age Ageing. 1983;12(2):124-30.
17. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327(23):1637-42.
18. Eriksson SA, Lindgren JU. Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women. Calcif Tissue Int. 1993;53(1):26-8.
19. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670-6.
20. Baeksgaard L, Andersen KP, Hylstrup L. Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporos Int. 1998;8(3):255-60.
21. Krieg MA, Jacquet AF, Bremgartner M, Cuttelod S, Thiebaut D, Burckhardt P. Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: a longitudinal study. Osteoporos Int. 1999;9(6):483-8.
22. Ringe JD, Coster A, Meng T, Schacht E, Umbach R. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int. 1999;65(4):337-40.
23. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15(6):1113-8.
24. Son SM, Chun YN. Effect of oral therapy with alphacalcidol or calcium in Korean elderly women with osteopenia and low dietary calcium. Nutr Res. 2001;21(10):1347-55.
25. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalysos II study. Osteoporos Int. 2002;13(3):257-64.
26. Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003;18(2):343-51.
27. Doetsch AM, Faber J, Lynnerup N, Watjen I, Bliddal H, Danneskiold-Samsoe B. The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study. Calcif Tissue Int. 2004;75(3):183-8.
28. Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study. Age Ageing. 2004;33(1):45-51.
29. Larsen ER, Mosekilde L, Foldsang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res. 2004;19(3):370-8.
30. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res. 2004;19(8):1221-30.
31. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365(9471):1621-8.
32. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ. 2005;330(7498):1003.
33. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-83.
34. Bolton-Smith C, McMurdie ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res. 2007;22(4):509-19.
35. Kukuljan S, Nowson CA, Bass SL, Sanders K, Nicholson GC, Seibel MJ, et al. Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older
men: a randomised controlled trial. Osteoporos Int. 2009;20(7):1241-51.

36. Salovaara K, Tuppurainen M, Karkkainen M, Rikkonen T, Sandini L, Sirola J, et al. Effect of vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial--the OSTPRE-FPS. J Bone Miner Res. 2010;25(7):1487-95.

Cite this article as: Shill LC, Purba NH, Sultana M, Hasan T, Rahman M, Sultana N. An update on osteoporosis research: effect of calcium plus vitamin D supplementation. Int J Community Med Public Health 2019;6:4120-8.